381 related articles for article (PubMed ID: 34334330)
1. A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
Cheung MC; Mittmann N; Owen C; Abdel-Samad N; Fraser GAM; Lam S; Crump M; Sperlich C; van der Jagt R; Prica A; Couban S; Woyach JA; Ruppert AS; Booth AM; Mandrekar SJ; McDonald G; Shepherd LE; Yen H; Chen BE; Hay AE
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):766-774. PubMed ID: 34334330
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.
Patel KK; Isufi I; Kothari S; Davidoff AJ; Gross CP; Huntington SF
Blood; 2020 Oct; 136(17):1946-1955. PubMed ID: 32518952
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Morabito F; Tripepi G; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Bossio S; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Al-Janazreh H; Vigna E; Martino EA; Cassin R; D Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Monti P; Menichini P; Olivieri J; Cutrona G; Rossi D; Cuneo A; Di Raimondo F; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
Am J Hematol; 2021 Aug; 96(8):E269-E272. PubMed ID: 33878220
[No Abstract] [Full Text] [Related]
5. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Woyach JA; Ruppert AS; Heerema NA; Zhao W; Booth AM; Ding W; Bartlett NL; Brander DM; Barr PM; Rogers KA; Parikh SA; Coutre S; Hurria A; Brown JR; Lozanski G; Blachly JS; Ozer HG; Major-Elechi B; Fruth B; Nattam S; Larson RA; Erba H; Litzow M; Owen C; Kuzma C; Abramson JS; Little RF; Smith SE; Stone RM; Mandrekar SJ; Byrd JC
N Engl J Med; 2018 Dec; 379(26):2517-2528. PubMed ID: 30501481
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran.
Fariman S; Momeni Nasab F; Faraji H; Afzali M
Value Health Reg Issues; 2023 Nov; 38():93-100. PubMed ID: 37806264
[TBL] [Abstract][Full Text] [Related]
7. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
Kabadi SM; Near A; Wada K; Burudpakdee C
Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
[TBL] [Abstract][Full Text] [Related]
8. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Fraser GAM; Chanan-Khan A; Demirkan F; Santucci Silva R; Grosicki S; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Loscertales J; Avigdor A; Rule S; Samoilova O; Pavlovsky MA; Goy A; Mato A; Hallek M; Salman M; Tamegnon M; Sun S; Connor A; Nottage K; Schuier N; Balasubramanian S; Howes A; Cramer P
Leuk Lymphoma; 2020 Dec; 61(13):3188-3197. PubMed ID: 32762271
[TBL] [Abstract][Full Text] [Related]
9. Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.
Singh M; Mealing S; Baculea S; Cote S; Whelan J
J Med Econ; 2017 Oct; 20(10):1066-1073. PubMed ID: 28720054
[TBL] [Abstract][Full Text] [Related]
10. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
Ruppert AS; Booth AM; Ding W; Bartlett NL; Brander DM; Coutre S; Brown JR; Nattam S; Larson RA; Erba H; Litzow M; Owen C; Kuzma CS; Abramson JS; Little RF; Smith SE; Stone RM; Byrd JC; Mandrekar SJ; Woyach JA
Leukemia; 2021 Oct; 35(10):2854-2861. PubMed ID: 34274940
[TBL] [Abstract][Full Text] [Related]
11. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Fraser G; Cramer P; Demirkan F; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Pavlovsky MA; Karlsson C; Hallek M; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Chanan-Khan A
Leukemia; 2019 Apr; 33(4):969-980. PubMed ID: 30315239
[TBL] [Abstract][Full Text] [Related]
12. Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.
Collett L; Howard DR; Munir T; McParland L; Oughton JB; Rawstron AC; Hockaday A; Dimbleby C; Phillips D; McMahon K; Hulme C; Allsup D; Bloor A; Hillmen P
Trials; 2017 Aug; 18(1):387. PubMed ID: 28830517
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Shanafelt TD; Wang XV; Kay NE; Hanson CA; O'Brien S; Barrientos J; Jelinek DF; Braggio E; Leis JF; Zhang CC; Coutre SE; Barr PM; Cashen AF; Mato AR; Singh AK; Mullane MP; Little RF; Erba H; Stone RM; Litzow M; Tallman M
N Engl J Med; 2019 Aug; 381(5):432-443. PubMed ID: 31365801
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study.
Hong Y; Chen X; Hong Y; Xiao X; Wang Y; You X; Mi J; Zhou T; Zheng P; Huang Z
BMC Health Serv Res; 2023 Dec; 23(1):1355. PubMed ID: 38049834
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
[No Abstract] [Full Text] [Related]
17. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
[TBL] [Abstract][Full Text] [Related]
18. Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Lavezzi SM; de Jong J; Neyens M; Cramer P; Demirkan F; Fraser G; Bartlett N; Dilhuydy MS; Loscertales J; Avigdor A; Rule S; Samoilova O; Goy A; Ganguly S; Salman M; Howes A; Mahler M; De Nicolao G; Poggesi I
Pharm Res; 2019 May; 36(7):93. PubMed ID: 31044267
[TBL] [Abstract][Full Text] [Related]
19. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
Huang Q; Emond B; Lafeuille MH; Gupta D; Lefebvre P; Sundaram M; Mato A
Curr Med Res Opin; 2020 Dec; 36(12):2009-2018. PubMed ID: 33044848
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain.
Moreno-Martínez E; De la Serna-Torroba J; Escudero-Vilaplana V; Hernández-Rivas JÁ; Sánchez-Cuervo M; Sánchez-Hernández R
Farm Hosp; 2022 Apr; 46(3):121-132. PubMed ID: 36183205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
